Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-03-17
1999-11-16
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3134
Patent
active
059859156
ABSTRACT:
The subject of the invention is a method for reducing mortality of cardiac origin in patients having a reduced left ventricular function after myocardial infarction, without rhythm disorders requiring an antiarrhythmic treatment, consisting in administering to said patients an effective amount of one or more active ingredients selected from benzofuran derivatives with antiarrhythmic activity and pharmaceutically acceptable salts thereof in combination with one or more pharmaceutically acceptable vehicles.
REFERENCES:
patent: 5223510 (1993-06-01), Gubin et al.
Am. J. Cardiol., vol. 72, No. 16, 1993, pp. 70f-74f, XP000607627.
Ann. Inter. Med., vol. 122, No. 9, 1995, pp. 689-700, XP000607576.
Chew et al.--J. Cardiovasc. Pharmacoc. vol. 4 (6), 1028-36 (Abstract), 1982.
Patterson et al--Circulation (Med. Sch., Univ. of Mich.) vol. 68 (4) 857-64 (Abstract), 1983.
Seidl et al.--Ptsch. Med. Wochenschr. vol. 120 (18), 656-60, Germany (Abstract), 1995.
Frangin Gerald
Munoz Alain
Henley III Raymond
Sanofi
LandOfFree
Use of antiarrhythmic compounds in the prevention of post-infarc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of antiarrhythmic compounds in the prevention of post-infarc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of antiarrhythmic compounds in the prevention of post-infarc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1325299